Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

459 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy.
van Leth F, Huisamen CB, Badaro R, Vandercam B, de Wet J, Montaner JS, Hall DB, Wit FW, Lange JM; 2NN Study Group. van Leth F, et al. Among authors: lange jm. J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):296-300. J Acquir Immune Defic Syndr. 2005. PMID: 15735447 Clinical Trial.
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, Wood R, Bloch M, Katlama C, Kastelein JJ, Schechter M, Murphy RL, Horban A, Hall DB, Lange JM, Reiss P. van Leth F, et al. Among authors: lange jm. PLoS Med. 2004 Oct;1(1):e19. doi: 10.1371/journal.pmed.0010019. Epub 2004 Oct 19. PLoS Med. 2004. PMID: 15526045 Free PMC article. Clinical Trial.
Efavirenz: a review.
Vrouenraets SM, Wit FW, van Tongeren J, Lange JM. Vrouenraets SM, et al. Among authors: lange jm. Expert Opin Pharmacother. 2007 Apr;8(6):851-71. doi: 10.1517/14656566.8.6.851. Expert Opin Pharmacother. 2007. PMID: 17425480 Review.
Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries.
Sow PS, Otieno LF, Bissagnene E, Kityo C, Bennink R, Clevenbergh P, Wit FW, Waalberg E, Rinke de Wit TF, Lange JM; Cohort Program to Evaluate Access to Antiretroviral Therapy and Education Project Team. Sow PS, et al. Among authors: lange jm. J Acquir Immune Defic Syndr. 2007 Mar 1;44(3):262-7. doi: 10.1097/QAI.0b013e31802bf109. J Acquir Immune Defic Syndr. 2007. PMID: 17146376 Clinical Trial.
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients.
van Leeuwen R, Katlama C, Murphy RL, Squires K, Gatell J, Horban A, Clotet B, Staszewski S, van Eeden A, Clumeck N, Moroni M, Pavia AT, Schmidt RE, Gonzalez-Lahoz J, Montaner J, Antunes F, Gulick R, Bánhegyi D, van der Valk M, Reiss P, van Weert L, van Leth F, Johnson VA, Sommadossi JP, Lange JM. van Leeuwen R, et al. Among authors: lange jm. AIDS. 2003 May 2;17(7):987-99. doi: 10.1097/00002030-200305020-00007. AIDS. 2003. PMID: 12700448 Clinical Trial.
459 results